Clinical trial · Interventional
Comparable Study of Different Radiation Dose in Esophageal Carcinoma
A Prospective, Randomised Phase 3 Study of High-dose Versus Standard-dose Radiation of Inoperable Esophageal Carcinoma Treated With Concurrent Chemoradiation
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Radiation therapy plus concurrent chemotherapy is now the standard therapy for patients with localized carcinoma of the esophagus selected for nonsurgical treatment. The standard radiation dose is 50-50.4Gy/1.8-2.0Gy/F.All of this were based on 2D radiation technology. Entering new century, 3D-CRT or IMRT has used on esophageal cancer. In China,the recommend radiation dose of concurrent chemoradiation was 60Gy. The study is a clinical phase III, randomized trial to compare the different radiation dose(60Gy vs 50Gy) of concurrent chemoradiation using 3D-CRT or IMRT in patients with unresectable esophageal carcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Carcinoma | Esophageal Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| concurrent chemotherapy with radiation | Drug | — | UNRESOLVED |
| intensity modulated radiation therapy in both arms | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- high-dose
- description
- concurrent chemoradiation:CT:DDP 25mg/m2 D1+docetaxel 25mg/m2 D1,Weekly for 5 wks;RT：60Gy/30F/6W(3D-CRT or IMRT).Then,2 cycles consolidation chemotherapy were used:DDP 75mg/m2 D1+docetaxel 75mg/m2 D1, Q3W
- interventionNames
- Radiation: intensity modulated radiation therapy in both arms
- Drug: concurrent chemotherapy with radiation
- type
- ACTIVE_COMPARATOR
- label
- standard dose
- description
- concurrent chemoradiation:CT:DDP 25mg/m2 D1+Docetaxel 25mg/m2 D1,Weekly for 5 wks;RT：50Gy/25F/5W(3D-CRT or IMRT).Then,2 cycles consolidation chemotherapy were used:DDP 5mg/m2 D1+Docetaxel75mg/m2 D1, Q3W
- interventionNames
- Radiation: intensity modulated radiation therapy in both arms
- Drug: concurrent chemotherapy with radiation
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Histological or cytologic diagnosis of esophageal carcinoma * ECOG performance status 0-1 * Age:18-70 years * Joined the study voluntarily and signed informed consent form * Patients must not have received any prior anticancer therapy * Unresectable disease, or refuse surgery.Stage Ⅰ-ⅣA（AJCC 2009） * Target lesions can be measured according to RECIST criteria * No serious system dysfunction and immuno-deficiency, Adequate organ function including the following: Hemoglobin ≥9 g/dL, WBC≥3x109/L, Neutrophils (ANC )≥1.5x109/L, platelet count ≥100x 109/L, TBIL\<1.5 x ULN, ALT and AST ≦ 2.5 x ULN, creatinine ≦ 1.5 x ULN * Use of an effective contraceptive for adults to prevent pregnancy * Life expectancy of more than 3 months Exclusion Criteria: * Multiple carcinomas of the esophagus, * Biopsy-proven invasion of the tracheobronchial tree or tracheoesophageal fistula, * Metastatic disease (M1), * A primary tumor that extended to within 2 cm of the gastroesophageal junction, * Prior chemotherapy, prior thoracic radiation, surgical resection of the primary tumor, * Concurrent pregnancy or lactation, history of a second malignancy other than nonmelanoma skin cancer
References
Publications (0)
Data not yet available